Aix-Marseille Universite
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Aug 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 8, 2027The maintenance fee for Argon Combined with Thrombectomy in the Event of Ischaemic Stroke (US 11,717,635) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Mito-honokiol compounds and methods of synthesis and use thereof (US 11,897,910) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
- 1 fee due Sep 3, 2027The maintenance fee for Neuroprotection by mitochondria-targeted metformin (US 10,576,093) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,274,114 | Modified Mito-Metformin Compounds and Methods of Synthesis and Use Thereof In force · High confidence | In force | High confidence | |
| US 10,836,782 | Mito-honokiol compounds and methods of synthesis and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,956,233 | Neuroprotection by Mitochondria-Targeted Metformin In force · High confidence | In force | High confidence | |
| US 10,576,093 | Neuroprotection by mitochondria-targeted metformin In force · High confidence | In force | High confidence | |
| US 11,897,910 | Mito-honokiol compounds and methods of synthesis and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,352,382 | Mito-lonidamine, compositions and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 11,083,739 | Mito-magnolol compounds and methods of synthesis and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,717,635 | Argon Combined with Thrombectomy in the Event of Ischaemic Stroke In force · High confidence | In force | High confidence | |
| US 12,656,334 | Method and Device for Determining Red Blood Cells Deformability In force · High confidence | In force | High confidence | |
| US 12,594,283 | Mitochondria-Targeted Atovaqone: A More Potent and More Effective Antitumor, Antimicrobial, and Antimalarial Drug In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 3 patents in force now held by others · 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 2 abandoned · 2 no status recorded